MedTrace Logo

Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia

NCT02868645 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-12-19

No results posted yet for this study

Summary

Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been shown that periostin is over expressed in fibrous component in patients bones ; but periostin has never been measured out in serum of patients, although it is easy to assess. This study aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia, and if it is more elevated in patients with severe forms of the disease.

Conditions

  • Bone Fibrous Dysplasia

Interventions

BIOLOGICAL

Blood sampling

Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-25
Primary Completion
2018-04-10
Completion
2018-04-10

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02868645 on ClinicalTrials.gov